Boston Scientific Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy BSX?
Source: PRnewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm will handle the case through a contingency fee arrangement, ensuring investors can seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations, highlighting management's misjudgment of the electrophysiology segment's growth rate.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.130
Low
94.00
Averages
108.14
High
132.00
Current: 69.130
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm will handle the case through a contingency fee arrangement, ensuring investors can seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations, highlighting management's misjudgment of the electrophysiology segment's growth rate.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its strong track record in this field.
- Investor Advice: Investors are advised to carefully select qualified counsel with a proven track record to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Reach Out
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, particularly for investors who purchased or acquired securities between July 23, 2025, and February 3, 2026, aiming to safeguard investor rights.
- Investor Contact Information: Investors who have suffered losses are encouraged by securities litigation partner Josh Wilson to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss available legal options.
- Class Action Deadline: The firm reminds investors that May 4, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against Boston Scientific, emphasizing the importance of timely action.
- Company Background: Boston Scientific Corporation (NYSE:BSX) is a well-known medical device manufacturer, and the legal issues it faces could negatively impact its stock price and investor confidence, prompting investors to stay informed about developments to protect their interests.
See More
Boston Scientific Class Action Reminder for Investors
- Lawsuit Background: Boston Scientific's Q4 2025 results, released on February 4, 2026, revealed disappointing U.S. electrophysiology sales, leading to a 17.6% drop in stock price to $75.50 per share, causing significant investor losses.
- Poor Market Performance: The company acknowledged slower market growth and increased competition in its report, despite prior claims of strong growth in the electrophysiology segment, indicating a major misjudgment that undermined investor confidence.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose the unsustainable growth rate of its electrophysiology segment and the emergence of new competitors, which limited growth potential.
- Investor Action Required: Investors must file a lead plaintiff motion by May 4, 2026, to pursue claims for losses incurred due to the company's misleading statements, highlighting the urgency and significance of legal action.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Boston Scientific and certain officers, seeking damages for investors who purchased securities between July 23, 2025, and February 3, 2026, highlighting significant investor concerns regarding financial transparency.
- False Statement Allegations: The complaint alleges that Boston Scientific made materially false and misleading statements during the relevant period, particularly regarding the sustainability of growth in its U.S. electrophysiology segment, revealing vulnerabilities under competitive and regulatory pressures that could undermine investor confidence.
- Growth Expectation Missteps: The lawsuit indicates that management's confidence in the U.S. electrophysiology division lacked a reasonable basis and failed to disclose adverse trends affecting procedure volumes and increasing competition, potentially impacting future revenue forecasts and exacerbating investor loss risks.
- Investor Action Call: Boston Scientific investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, demonstrating a proactive and urgent approach to safeguarding their rights amidst the allegations.
See More
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit due to false statements made between July 23, 2025, and February 3, 2026, with investors able to apply as lead plaintiffs by May 4, 2026, indicating significant legal risks that could impact stock price and market confidence.
- Financial Performance Miss: On February 4, 2026, Boston Scientific reported Q4 and full-year 2025 results, with GAAP net income at $672 million, an 18.7% increase year-over-year, but EPS of $0.45 fell short of the guidance range of $0.48 to $0.52, leading to a stock price drop of over 17%, reflecting market concerns about growth prospects.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the U.S. electrophysiology market, resulting in a decline in market share and hindering the company's goal of growing at “twice the market rate,” highlighting intensified competitive pressures within the industry.
- Legal Representation Strength: Robbins Geller, representing investors, has recovered $8.4 billion over the past five years, showcasing its strong capabilities in securities fraud and shareholder rights litigation, which may significantly influence the legal outcomes for Boston Scientific.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, that they must apply to be lead plaintiff by May 4, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants are not required to pay any upfront fees or costs, as the law firm will handle the case through a contingency fee arrangement, ensuring investors can seek compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, leading to investor losses when the company missed net income expectations, highlighting management's misjudgment of the electrophysiology segment's growth rate.
- Law Firm Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its success and resource advantages in handling such cases.
See More
Boston Scientific Class Action Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Boston Scientific stock between July 23, 2025, and February 3, 2026, to apply as lead plaintiffs by May 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Boston Scientific made false and misleading statements during the class period, concealing the true state of its U.S. Electrophysiology segment, which led to investor losses when the company missed net income expectations.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its strong track record in this field.
- Investor Advice: Investors are advised to carefully select qualified counsel with a proven track record to ensure effective legal support in class actions, avoiding firms that merely act as intermediaries.
See More
Faruqi & Faruqi Encourages Boston Scientific Investors to Reach Out
- Legal Investigation: Faruq & Faruqi, LLP is investigating potential claims against Boston Scientific Corporation, particularly for investors who purchased or acquired securities between July 23, 2025, and February 3, 2026, aiming to safeguard investor rights.
- Investor Contact Information: Investors who have suffered losses are encouraged by securities litigation partner Josh Wilson to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss available legal options.
- Class Action Deadline: The firm reminds investors that May 4, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action filed against Boston Scientific, emphasizing the importance of timely action.
- Company Background: Boston Scientific Corporation (NYSE:BSX) is a well-known medical device manufacturer, and the legal issues it faces could negatively impact its stock price and investor confidence, prompting investors to stay informed about developments to protect their interests.
See More
Boston Scientific Class Action Reminder for Investors
- Lawsuit Background: Boston Scientific's Q4 2025 results, released on February 4, 2026, revealed disappointing U.S. electrophysiology sales, leading to a 17.6% drop in stock price to $75.50 per share, causing significant investor losses.
- Poor Market Performance: The company acknowledged slower market growth and increased competition in its report, despite prior claims of strong growth in the electrophysiology segment, indicating a major misjudgment that undermined investor confidence.
- False Statement Allegations: The class action lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose the unsustainable growth rate of its electrophysiology segment and the emergence of new competitors, which limited growth potential.
- Investor Action Required: Investors must file a lead plaintiff motion by May 4, 2026, to pursue claims for losses incurred due to the company's misleading statements, highlighting the urgency and significance of legal action.
See More
Boston Scientific Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has filed a class action lawsuit against Boston Scientific and certain officers, seeking damages for investors who purchased securities between July 23, 2025, and February 3, 2026, highlighting significant investor concerns regarding financial transparency.
- False Statement Allegations: The complaint alleges that Boston Scientific made materially false and misleading statements during the relevant period, particularly regarding the sustainability of growth in its U.S. electrophysiology segment, revealing vulnerabilities under competitive and regulatory pressures that could undermine investor confidence.
- Growth Expectation Missteps: The lawsuit indicates that management's confidence in the U.S. electrophysiology division lacked a reasonable basis and failed to disclose adverse trends affecting procedure volumes and increasing competition, potentially impacting future revenue forecasts and exacerbating investor loss risks.
- Investor Action Call: Boston Scientific investors are encouraged to apply to be lead plaintiffs by May 4, 2026, to share in any potential recovery from the lawsuit, demonstrating a proactive and urgent approach to safeguarding their rights amidst the allegations.
See More
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit due to false statements made between July 23, 2025, and February 3, 2026, with investors able to apply as lead plaintiffs by May 4, 2026, indicating significant legal risks that could impact stock price and market confidence.
- Financial Performance Miss: On February 4, 2026, Boston Scientific reported Q4 and full-year 2025 results, with GAAP net income at $672 million, an 18.7% increase year-over-year, but EPS of $0.45 fell short of the guidance range of $0.48 to $0.52, leading to a stock price drop of over 17%, reflecting market concerns about growth prospects.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the U.S. electrophysiology market, resulting in a decline in market share and hindering the company's goal of growing at “twice the market rate,” highlighting intensified competitive pressures within the industry.
- Legal Representation Strength: Robbins Geller, representing investors, has recovered $8.4 billion over the past five years, showcasing its strong capabilities in securities fraud and shareholder rights litigation, which may significantly influence the legal outcomes for Boston Scientific.
See More
